[1]
|
国务院联防联控机制综合组. 新型冠状病毒感染诊疗方案(试行第十版)[EB/OL]. (2023-01-06)[2023-01-06]. http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/460b0e7b19bd42f3bba00c1efb9b6811.pdf. |
[2]
|
中华人民共和国国家卫生健康委员会. 关于印发对新型冠状病毒感染实施"乙类乙管"总体方案的通知[EB/OL]. (2022-12-26)[2023-01-05]. http://www.nhc.gov.cn/xcs/zhengcwj/202212/e97e4c449d7a475794624b8ea12123c6.shtml. |
[3]
|
Cheng A, Caruso D, Mcdougall C. Outpatient Management of COVID-19: Rapid Evidence Review[J]. Am Fam Physician, 2020, 102: 478-486. |
[4]
|
Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care[J]. BMJ, 2020, 368: m1182. |
[5]
|
Chinese Center for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals[EB/OL]. (2022-12-05)[2023-01-05]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/und-er-lyingconditions.html#complete-list-disabilities. |
[6]
|
NIH. Coronavirus Disease 2019(COVID-19)Treatment Guidelines[EB/OL]. (2022-12-28)[2023-01-05]. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. |
[7]
|
NICE. COVID-19 rapid guideline: managing COVID-19[EB/OL]. (2022-11-11)[2023-01-05]. https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guide-line-managing-covid19-pdf-51035553326. |
[8]
|
SIGN. Assessment of COVID-19 in primary care[EB/OL]. (2022-03-28)[2023-01-05]. https://www.sign.ac.uk/media/1969/covid-primary-care-assess-update-v4-mar-22-v2.pdf. |
[9]
|
中华人民共和国国家卫生健康委员会. 基层医疗卫生机构急重患者判断及转诊技术标准: WS/T 810—2022 [S]. |
[10]
|
北京协和医院呼吸与危重症医学科. 北京协和医院呼吸与危重症医学科新冠肺炎诊疗参考方案(2022年12月版)[EB/OL]. (2022-12-26)[2023-01-05]. https://mp.weixin.qq.com/s/8IwoZ6LE1RxDaXxhkl-Itw. |
[11]
|
World Health Organization. Therapeutics and COVID-19: living guideline[EB/OL]. (2022-07-14)[2023-01-06]. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4. |
[12]
|
Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19[J]. BMJ, 2020, 370: m3379. |
[13]
|
Chimenti C, Magnocavallo M, Ballatore F, et al. Prevalence and Clinical Implications of COVID-19 Myocarditis[J]. Card Electrophysiol Clin, 2022, 14: 53-62. doi: 10.1016/j.ccep.2021.11.001 |
[14]
|
Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection[J]. Nat Med, 2022, 28: 410-422. doi: 10.1038/s41591-021-01630-0 |
[15]
|
Ammirati E, Lupi L, Palazzini M, et al. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis[J]. Circulation, 2022, 145: 1123-1139. doi: 10.1161/CIRCULATIONAHA.121.056817 |
[16]
|
Silva F, Brito BB, Santos MLC, et al. COVID-19 gastrointestinal manifestations: a systematic review[J]. Rev Soc Bras Med Trop, 2020, 53: e20200714. doi: 10.1590/0037-8682-0714-2020 |
[17]
|
UpToDate. 2019冠状病毒病(COVID-19): 胃肠道症状和并发症[EB/OL]. (2021-03-24)[2023-01-05]. https://www.uptodate.cn/contents/zh-Hans/covid-19-gastrointestinal-symptoms-and-complications?search=COVID-19%20%E6%B6%88%E5%8C%96%E7%B3%BB%E7%BB%9F%E5%B9%B6%E5%8F%91%E7%97%87&topicRef=127965&source=see_link. |
[18]
|
Phipps MM, Barraza LH, Lasota ED, et al. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort[J]. Hepatology, 2020, 72: 807-817. doi: 10.1002/hep.31404 |
[19]
|
Harapan H, Fajar JK, Supriono S, et al. The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis[J]. Rev Med Virol, 2022, 32: e2304. |
[20]
|
中国医师协会肾脏内科医师分会. 新型冠状病毒肺炎合并肾损伤的预防和诊治专家建议[J]. 中华医学杂志, 2020, 100: 2161-2168. |
[21]
|
Ali MAM, Spinler SA. COVID-19 and thrombosis: From bench to bedside[J]. Trends Cardiovasc Med, 2021, 31: 143-160. doi: 10.1016/j.tcm.2020.12.004 |
[22]
|
UpToDate. COVID-19: 神经系统并发症及神经系统疾病管理[EB/OL]. (2022-04-27). [2023-01-05]. https://www.uptodate.com/contents/zh-Hans/covid-19-neurologic-complications-and-management-of-neurologic-conditions?search=COVID%2019%20%20%E6%B6%88%E5%8C%96&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7#H698977925. |
[23]
|
Yasari F, Akbarian M, Abedini A, et al. The role of electrolyte imbalances in predicting the severity of COVID-19 in the hospitalized patients: a cross-sectional study[J]. Sci Rep, 2022, 12: 14732. doi: 10.1038/s41598-022-19264-8 |
[24]
|
de Carvalho H, Richard MC, Chouihed T, et al. Electrolyte imbalance in COVID-19 patients admitted to the Emergency Department: a case-control study[J]. Intern Emerg Med, 2021, 16: 1945-1950. doi: 10.1007/s11739-021-02632-z |
[25]
|
Malinowska J, Małecka-Giełdowska M, Bańkowska D, et al. Hypermagnesemia and hyperphosphatemia are highly preva-lent in patients with COVID-19 and increase the risk of death[J]. Int J Infect Dis, 2022, 122: 543-549. doi: 10.1016/j.ijid.2022.06.057 |
[26]
|
Christ-Crain M, Hoorn EJ, Sherlock M, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2020, 183: G9-G15. doi: 10.1530/EJE-20-0338 |
[27]
|
孙英贤, 赵连友, 李昭, 等. 新型冠状病毒肺炎疫情防控常态化下高血压管理中国专家共识[J]. 中华高血压杂志, 2020, 28: 1014-1018. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202011005.htm |
[28]
|
Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews[J]. Diabetes Care, 2021, 44: 2790-2811. doi: 10.2337/dc21-0930 |
[29]
|
王卫庆, 单忠艳, 王广, 等. 新型冠状病毒肺炎疫情期间糖尿病基层管理专家建议[J]. 中华内分泌代谢杂志, 2020, 39: 185-190. https://www.cnki.com.cn/Article/CJFDTOTAL-SHHL202107003.htm |
[30]
|
Xie D, Choi HK, Dalbeth N, et al. Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Indivi-duals: A General Population Study[J]. Arthritis Rheumatol, 2023, 75: 122-132. doi: 10.1002/art.42339 |
[31]
|
UpToDate. 哮喘管理概述[EB/OL]. (2022-11-02)[2023-01-05]. https://www.uptodate.cn/contents/zh-Hans/an-overview-of-asthma-management?sectionName=%E4%B8%8ECOVID-19%E5%A4%A7%E6%B5%81%E8%A1%8C%E7%9B%B8%E5%85%B3%E7%9A%84%E5%BB%BA%E8%AE%AE&search=COVID-19,%20%E5%93%AE%E5%96%98&topicRef=127454&anchor=H1664899454&source=see_link#H1664899454. |
[32]
|
UpToDate. 稳定期COPD的管理概述[EB/OL]. (2022-12-14)[2023-01-05]. https://www.uptodate.cn/contents/zh-Hans/stable-copd-overview-of-management?sectionName=COVID-19%E7%9B%B8%E5%85%B3%E7%9A%84%E5%BB%BA%E8%AE%AE&search=COVID-19,%20%E5%93%AE%E5%96%98&topicRef=127454&anchor=H3400843522&source=see_link#H3400843522. |
[33]
|
UpToDate. COVID-19: 急性肾损伤、肾小球疾病和高血压相关问题[EB/OL]. (2022-12-23)[2023-01-05]. https://www.uptodate.cn/contents/zh-Hans/covid-19-issues-related-to-acute-kidney-injury-glomerular-disease-and-hypertension?search=COVID-19,%20%E5%93%AE%E5%96%98&topicRef=127454&source=see_link#H2824154764. |
[34]
|
UpToDate. 2019冠状病毒病(COVID-19): 系统性风湿病成人患者的诊疗[EB/OL]. (2022-10-25)[2023-01-05]. https://www.uptodate.cn/contents/zh-Hans/covid-19-care-of-adult-patients-with-systemic-rheumatic-disease. |
[35]
|
Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1[J]. Arthritis Rheumatol, 2020, 72: 1241-1251. doi: 10.1002/art.41301 |
[36]
|
National Comprehensive Cancer Network. NCCN Guidelines Version 3.2022. Management of Concurrent COVID-19 and Cancer in Patients[EB/OL]. (2022-10-28)[2023-01-05]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457. |
[37]
|
D'souza R, Ashraf R, Rowe H, et al. Pregnancy and COVID-19: pharmacologic considerations [J]. Ultrasound Obstet Gynecol, 2021, 57: 195-203. doi: 10.1002/uog.23116 |
[38]
|
北京市卫生健康委员会. 新型冠状病毒感染者恢复期健康管理专家指引(第一版)[EB/OL]. (2022-12-29)[2023-01-05]. http://wjw.beijing.gov.cn/xwzx_20031/wnxw/202212/t20221229_2886740.html. |
[39]
|
世界卫生组织. 康复指导手册: COVID-19相关疾病的自我管理(第二版)[EB/OL]. (2021-11-29)[2023-01-05]. https://apps.who.int/iris/bitstream/handle/10665/349695/WHO-EURO-2021-855-40590-62244-chi.pdf?sequence=1&isAllowed=y. |
[40]
|
Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22: e102-e7. doi: 10.1016/S1473-3099(21)00703-9 |
[41]
|
Chinese Center for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers[EB/OL]. (2022-12-26)[2023-01-05]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. |